Press Releases
SABCS15: ONT-380 Phase I results support progression to Phase II in advanced HER2+ breast cancer
Phase I data regarding the experimental cancer agent ONT-380 were presented recently at the 2015 San Antonio Breast Cancer Symposium, indicating initial...
News
Regional variations in US cancer imaging data: a warning for imaging overuse
Danil V Makarov speaks to Gemma Westcott, Commissioning Editor: Danil V Makarov is an Assistant Professor and Director of Surgical Research in the Department...
Clinical Trials
CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial
CTI BioPharma Corp. announced its plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) following a productive...
Research Insight
ASCO hail cancer immunotherapy as clinical cancer advance of the year
In their just-released Clinical Cancer Advances 2016: ASCO’s Annual Report on Progress Against Cancer the American Society of Clinical Oncology (ASCO) has today hailed...
Press Releases
Early diagnosis of bowel cancer in the England – Report Highlights
The importance of national screening Data published by Cancer Research UK and Public Health England’s National Cancer Intelligence Network have reported, for the first...
Research Insight
Study Finds High Proportion of Advanced Breast Cancers in sub-Saharan Africa
In one of the first studies of its kind, a new report finds a large majority of breast cancers in Cote d’Ivoire and Republic...
Clinical Trials
Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
Merck known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read